Technical Analysis for ABUS - Arbutus Biopharma Corporation

Grade Last Price % Change Price Change
grade F 3.87 4.59% 0.17
ABUS closed up 4.59 percent on Friday, February 15, 2019, on 69 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ABUS trend table...

Date Alert Name Type % Chg
Feb 15 Crossed Above 20 DMA Bullish 0.00%
Feb 14 Fell Below 20 DMA Bearish 4.59%
Feb 13 50 DMA Resistance Bearish -0.51%
Feb 13 Shooting Star Candlestick Bearish -0.51%
Feb 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.51%
Feb 13 Upper Bollinger Band Touch Strength -0.51%
Feb 12 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.51%
Feb 12 Narrow Range Bar Range Contraction -0.51%
Feb 12 NR7 Range Contraction -0.51%
Feb 12 NR7-2 Range Contraction -0.51%

Older signals for ABUS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company's products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Biopharmaceutical Medical Specialties Infectious Diseases Hepatitis B Hepatocellular Carcinoma Hypercholesterolemia PLK1 Sexually Transmitted Diseases And Infections Zoonoses Arbutus Biopharma Liver Cancer Primary Hyperoxaluria Transthyretin Amyloidosis Tropical Diseases
Is ABUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 12.6
52 Week Low 3.2
Average Volume 193,733
200-Day Moving Average 6.6012
50-Day Moving Average 3.9242
20-Day Moving Average 3.7505
10-Day Moving Average 3.843
Average True Range 0.2616
ADX 10.58
+DI 22.6006
-DI 21.429
Chandelier Exit (Long, 3 ATRs ) 3.4052
Chandelier Exit (Short, 3 ATRs ) 4.1848
Upper Bollinger Band 4.0582
Lower Bollinger Band 3.4428
Percent B (%b) 0.69
BandWidth 16.408479
MACD Line -0.0178
MACD Signal Line -0.0436
MACD Histogram 0.0258
Fundamentals Value
Market Cap 212.95 Million
Num Shares 55 Million
EPS -5.07
Price-to-Earnings (P/E) Ratio -0.76
Price-to-Sales 164.81
Price-to-Book 1.74
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.20
Resistance 3 (R3) 4.17 4.02 4.15
Resistance 2 (R2) 4.02 3.94 4.04 4.13
Resistance 1 (R1) 3.95 3.89 3.99 3.98 4.11
Pivot Point 3.80 3.80 3.82 3.82 3.80
Support 1 (S1) 3.73 3.72 3.77 3.76 3.63
Support 2 (S2) 3.58 3.67 3.60 3.61
Support 3 (S3) 3.51 3.58 3.60
Support 4 (S4) 3.54